Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC). Methods: We randomized a total of 389 patients to groups treated by GTS and ondansetron before HEC. The primary endpoint was the percentage of patients achieving complete response (CR; no retching/vomiting/rescue medication) of CINV from the time of chemotherapy initiation to 24 hours after the last administration of chemotherapy (prespecified non-inferiority margin of 15%). Quality of life (QoL) was also assessed using the Functional Living Index-Emesis (FLIE). Results: The per protocol analysis included 152 (47.80%) and 166 patients (52.20%) in the GTS and ondansetron groups, respectively. In the full analysis set, the most common diagnosis, regimen, and period of chemotherapy were lung cancer (149 patients, 40.27%), cisplatin-based regimen (297 patients, 80.27%), and 1 day chemotherapy (221 patients, 59.73%). The CR rates were 86.84% and 90.36% in the GTS and ondansetron groups, respectively; the treatment difference was −3.52% (95% confidence interval, −10.52 to 3.48) and met the primary endpoint, indicating that GTS was not inferior to ondansetron. Patient satisfaction, assessed on the FLIE, showed significantly higher scores in the GTS group compared to the ondansetron group (mean ± standard deviation, 1,547.38 ± 306.00 and 1,494.07 ± 312.05 mm, respectively; p = 0.0449). Conclusions: GTS provided effective, safe, and well-tolerated control of CINV and improved the QoL in HEC.
Abstract
Background/Aims: We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC). Methods: We randomized a total of 389 patients to groups treated by GTS and ondansetron before HEC. The primary endpoint was the percentage of patients achieving complete response (CR; no retching/vomiting/rescue medication) of CINV from the time of chemotherapy initiation to 24 hours after the last administration of chemotherapy (prespecified non-inferiority margin of 15%). Quality of life (QoL) was also assessed using the Functional Living Index-Emesis (FLIE). Results: The per protocol analysis included 152 (47.80%) and 166 patients (52.20%) in the GTS and ondansetron groups, respectively. In the full analysis set, the most common diagnosis, regimen, and period of chemotherapy were lung cancer (149 patients, 40.27%), cisplatin-based regimen (297 patients, 80.27%), and 1 day chemotherapy (221 patients, 59.73%). The CR rates were 86.84% and 90.36% in the GTS and ondansetron groups, respectively; the treatment difference was −3.52% (95% confidence interval, −10.52 to 3.48) and met the primary endpoint, indicating that GTS was not inferior to ondansetron. Patient satisfaction, assessed on the FLIE, showed significantly higher scores in the GTS group compared to the ondansetron group (mean ± standard deviation, 1,547.38 ± 306.00 and 1,494.07 ± 312.05 mm, respectively; p = 0.0449). Conclusions: GTS provided effective, safe, and well-tolerated control of CINV and improved the QoL in HEC.
참고문헌 (19)
- Jantunen IT, "An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting", Eur J Cancer, 33, pp.66~74 (1997)
- "Clinical practice guidelines in oncology: antiemesis V.2.2020" (2020)[URL]
- Howell J, "Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting", J Oncol Pharm Pract, 15, pp.223~231 (2009)
- Boccia RV, "Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy : a randomized, double-blind, phase III study", Support Care Cancer, 19, pp.1609~1617 (2011)
- Kim JE, "A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients", Support Care Cancer, 23, pp.1769~1777 (2015)
- Seol YM, "Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy : a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study", Support Care Cancer, 24, pp.945~952 (2016)
- Hesketh PJ, "Proposal for classifying the acute emetogenicity of cancer chemotherapy", J Clin Oncol, 15, pp.103~109 (1997)
- Lindley CM, "Quality of life consequences of chemotherapy-induced emesis", Qual Life Res, 1, pp.331~340 (1992)
- "Center for Drug Evaluation and Research, Approval package for: application number 21-372, palonosetron: statistical review" (2013)[URL]
- Gralla RJ, "Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin : analysis of combined data from two phase III randomized clinical trials", Cancer, 104, pp.864~868 (2005)
- Hesketh PJ, "The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting : a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052Study Group", J Clin Oncol, 21, pp.4112~4119 (2003)
- Poli-Bigelli S, "Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America", Cancer, 97, pp.3090~3098 (2003)
- Schmoll HJ, "Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in highdose cisplatin treatment", Ann Oncol, 17, pp.1000~1006 (2006)
- "Sancuso. Approval information" (2014)[URL]
- Tyers MB, "Pharmacological and anti-emetic properties of ondansetron", Eur J Cancer Clin Oncol, 25(Suppl 1), pp.S15~S19 (1989)
- Jordan K, "Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting : past, present, and future recommendations", Oncologist, 12, pp.1143~1150 (2007)
- Chua DT, "The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy : a randomized crossover trial", Br J Clin Pharmacol, 41, pp.403~408 (1996)
- Kraut L, "Anti-emetics for cancer chemotherapy-induced emesis : potential of alternative delivery systems", Drugs, 61, pp.1553~1562 (2001)
- Kaestli LZ, "Use of transdermal drug formulations in the elderly", Drugs Aging, 25, pp.269~280 (2008)